Fig. 3
From: Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
Percentage of teriflunomide 14 mg-treated patients with 12-week CDW (core and extension period). CDW confirmed disability worsening, DMT disease-modifying therapy